Generic Drugmakers to Make Cheap Versions of Merck's Covid-19 Pill Molnupiravir for Poorer Nations
2 years, 11 months ago

Generic Drugmakers to Make Cheap Versions of Merck's Covid-19 Pill Molnupiravir for Poorer Nations

News 18  

A UN-backed agency has struck a deal for nearly 30 generic drugmakers to make low-cost versions of Merck & Co’s Covid-19 pill molnupiravir for poorer nations, widening access to a drug seen as a weapon in fighting the pandemic. A molnupiravir course of 40 pills for five days is expected to cost about $20 in poorer nations, an MPP official involved in the talks with drugmakers told Reuters, citing initial estimates from drugmakers, which are subject to change. NO ROYALTIES, FOR NOW The developers of molnupiravir, which alongside Merck are US firm Ridgeback Biotherapeutics and Emory University, will not receive royalties for the sale of the low-cost versions made by generic drugmakers while Covid-19 remains classified as a public health emergency of international concern by WHO. The MPP spokesperson said there was no firm estimate yet of the likely output from generics makers covered by the deal, but that poorer nations’ demand was expected to be largely covered.

India Deal Merck Generic Pill Mpp Poorer Nations Drugmakers Molnupiravir Generic Drugmakers  poorer  cheap  merck  molnupiravir  versions  pill  nations  generic  produce  drugmakers  mpp  covid19  mercks  deal

History of this topic

New injectable variant of HIV-preventing drug in ‘poorest’ countries soon, claims health official
1 week ago

New injectable variant of HIV-preventing drug in ‘poorest’ countries soon, claims health official

Hindustan Times  

A new variant of Lenacapavir, a drug used to treat multi-resistant HIV, could be available for use in the world’s poorest countries by the end of 2025 or early 2026. Gilead Sciences is now seeking approval for a global rollout for its injectable version from the United States Food and Drug Administration and the World Health Organisation. To address high …

COVID-19 treatments to enter the market with a hefty price tag
1 year, 1 month ago

COVID-19 treatments to enter the market with a hefty price tag

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Please try again later {{ …

COVID-19 treatments to enter the market with a hefty price tag
1 year, 1 month ago

COVID-19 treatments to enter the market with a hefty price tag

Associated Press  

WASHINGTON — The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag. The less commonly used COVID-19 treatment Lagevrio, manufactured by Merck, also will hit the market next week. “Pfizer is committed to a smooth commercial transition and is working collaboratively with the U.S. …

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase
1 year, 2 months ago

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase

CNN  

CNN — The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday. Pfizer noted that the list price “does not necessarily reflect the price a patient will pay” and said it’s working to secure health insurance arrangements that would come …

Frustration is rising over Covid drug shortages in China, and there are no easy answers
1 year, 11 months ago

Frustration is rising over Covid drug shortages in China, and there are no easy answers

CNN  

Editor’s Note: Editor’s Note: A version of this story appeared in CNN’s Meanwhile in China newsletter, a three-times-a-week update exploring what you need to know about the country’s rise and how it impacts the world. On Monday, Pfizer’s CEO Albert Bourla said the company had ramped up exports, sending millions of courses of Paxlovid to China in the past couple …

Chinese turning to Indian drugs on black market amid Covid spike
1 year, 11 months ago

Chinese turning to Indian drugs on black market amid Covid spike

India Today  

Chinese nations have now turned to the black market for generic Covid-19 drugs as the country is dealing with an unprecedented outbreak with limited supplies of approved antivirals. China approved two Covid-19 antivirals this year - Pfizer’s Paxlovid and Azvudine, an HIV drug from Chinese firm Genuine Biotech. Topics like “anti-Covid Indian generic drugs sold at 1,000 yuan per box” …

Antiviral Covid treatment now available in the Netherlands for €1,250
2 years ago

Antiviral Covid treatment now available in the Netherlands for €1,250

NL Times  

The antiviral medication approved to treat Covid-19 is now available on the Dutch market, the Dutch Association of General Practitioners confirmed on Thursday. Treatment using the drug Paxlovid, produced by Pfizer, will cost 1,242 euros, and there are strict rules about who qualifies to get those costs covered by insurers. Two 150-milligram tablets of Paxlovid and one 100-milligram tablet of …

Domestically developed drug joins virus battle
2 years, 4 months ago

Domestically developed drug joins virus battle

China Daily  

A first batch of 660 tourists stranded in Haikou, Hainan province, due to a recent outbreak of COVID-19 on the island, have their ticket information checked at Haikou Meilan International Airport on Friday before boarding flights back home. China's first domestically developed COVID-19 antiviral, approved by the top drug regulator last month and added to the national COVID-19 treatment protocol …

Pfizer to offer low-cost medicines, vaccines to poor nations
2 years, 6 months ago

Pfizer to offer low-cost medicines, vaccines to poor nations

Associated Press  

Pfizer said Wednesday that it will provide nearly two dozen products, including its top-selling COVID-19 vaccine and treatment, at not-for-profit prices in some of the world’s poorest countries. The drugmaker announced the program at the World Economic Forum’s annual gathering in Davos, Switzerland, and said it was aimed at improving health equity in 45 lower-income countries. “What we discovered through …

Pfizer to offer low-cost drugs to 45 lower-income nations
2 years, 7 months ago

Pfizer to offer low-cost drugs to 45 lower-income nations

Al Jazeera  

US pharmaceutical giant says it will sell patented drugs on a not-for-profit basis to world’s poorest countries. US pharmaceutical giant Pfizer has said it would sell its patented drugs on a not-for-profit basis to the world’s poorest countries, as part of a new initiative announced at the World Economic Forum in Davos. “An Accord for a Healthier World” focuses on …

What is Paxlovid and Who Can Take Pfizer’s Covid-19 Wonder Drug ‘Strongly Recommended’ by WHO?
2 years, 8 months ago

What is Paxlovid and Who Can Take Pfizer’s Covid-19 Wonder Drug ‘Strongly Recommended’ by WHO?

News 18  

Paxlovid, Pfizer’s Covid-19 antiviral pill, has been “strongly recommended” by the World Health Organization for patients with milder forms of the disease who are still at high risk of hospitalisation. WHO experts have said that Pfizer’s oral treatment prevents hospitalisation more than the “available alternatives, has fewer concerns with respect to harms than Molnupiravir, and is easier to administer than …

COVID-19 pills could be a game-changer, but doctors trying to use them face hurdles
2 years, 9 months ago

COVID-19 pills could be a game-changer, but doctors trying to use them face hurdles

LA Times  

Jeff Carlson, a Type 1 diabetic with heart stents, came down with COVID-19 in January, but recovered quickly after being treated with Merck’s molnupiravir. With vaccines and treatments available, “we can make this much more manageable in the future, if people are willing to take care of themselves,” said Dr. Bryan Jarabek, who helps lead COVID-19 treatment and vaccination efforts …

Natco, 9 others chosen to supply COVID-19 drug
2 years, 11 months ago

Natco, 9 others chosen to supply COVID-19 drug

The Hindu  

January 20, 2022 10:45 pm | Updated January 21, 2022 12:52 am IST - HYDERABAD United Nations-backed public health organisation Medicines Patent Pool has signed sublicence agreements with 10 generic drugmakers in India for the manufacturing of COVID-19 antiviral oral drug molnupiravir and supply in 105 low- and-middle-income countries. Natco, Strides, Biophore, SMS Pharmaceuticals, Laurus, Lupin, MSN, Arene Lifesciences, BDR …

Cheap version of Merck Covid pill to be made for poorer nations
2 years, 11 months ago

Cheap version of Merck Covid pill to be made for poorer nations

India Today  

A UN-backed agency has struck a deal for nearly 30 generic drugmakers to make low-cost versions of Merck & Co's Covid-19 pill molnupiravir for poorer nations, widening access to a drug seen as a weapon in fighting the pandemic. The agreement, negotiated by the UN-backed Medicines Patent Pool with Merck, allows 27 generic drugmakers from India, China and other countries …

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India
2 years, 11 months ago

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

Deccan Chronicle  

Hyderabad: Aurobindo Pharma Limited has launched COVID-19 treatment drug Molnupiravir under brand name "Molnaflu" in India. Earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore, a subsidiary of Merck & Co. to manufacture and supply Molnupiravir to over 100 low and middle-income countries, including India. K Nithyananda Reddy, Vice Chairman and Managing …

Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip
2 years, 11 months ago

Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip

India TV News  

Molnupiravir, the world’s first and only oral antiviral to be approved by the US FDA, UK MHRA and Indian CDSCO for treatment of COVID-19, is set for a launch. Last week, the Drugs Controller General of India, based on the review of clinical data of molnupiravir, approved molnupiravir for treatment of adult patients with Covid-19, with SpO2 > 93% and …

EXPLAINED: As Covid Antiviral Molnupiravir Launches In India, Here's All You Need To Know About The Pill
2 years, 11 months ago

EXPLAINED: As Covid Antiviral Molnupiravir Launches In India, Here's All You Need To Know About The Pill

News 18  

Days after it received an emergency use nod from the Indian drugs regulator, the antiviral molnupiravir has already hit the markets with more than a dozen Indian companies working on rolling out the pill by taking advantage of the patent waiver offered by its American makers for production in low- and middle-income countries. Molnupiravir has received an emergency nod in …

Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week
2 years, 11 months ago

Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week

News 18  

Mankind Pharma’s chairman has said the company’s will launch the cheapest Molnupiravir, the Covid-19 antiviral drug, at Rs 35 per capsule, the Economic Times said in a report. Molnupiravir, developed by MSD and Ridgeback Biotherapeutics, has been approved by the UK Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration for the treatment of mild-to-moderate Covid-19 …

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know
2 years, 11 months ago

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know

Firstpost  

Molnupiravir, developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US pharma giant Merck, was approved for emergency use in India on Tuesday The Drug Controller General of India had earlier this week approved Molnupiravir for restricted use in an emergency situation in India. Brinton Pharmaceuticals on Thursday said it will launch its generic version of anti-COVID-19 pill Molnupiravir …

Covid Pill Molnupiravir’s Treatment for 5 Days May Cost Rs 1,600-Rs 3,000
2 years, 11 months ago

Covid Pill Molnupiravir’s Treatment for 5 Days May Cost Rs 1,600-Rs 3,000

News 18  

The anti-viral Covid pill, Molnupiravir, may be priced Rs 40 to Rs 75 per tablet thus making the cost of the entire treatment around Rs 3,000 for five days, the head of Optimus Pharma, one of the 13 companies launching the drug in India, told News18. The recommended dose of Molnupiravir is 800 milligram twice a day for five days, …

Approved by India, Full Treatment of Anti-Viral Drug Molnupiravir May Cost Up to Rs 3,000: Report
2 years, 11 months ago

Approved by India, Full Treatment of Anti-Viral Drug Molnupiravir May Cost Up to Rs 3,000: Report

News 18  

Anti-viral drug Molnupiravir, which has got the green flag from the Drug Controller General of India for emergency use approval to treat Covid-19, is expected to cost between ₹2,000 and ₹3,000 for full treatment. Earlier, Merck had said it “plans to implement a tiered pricing approach based on World Bank country income criteria to reflect countries’ relative ability to finance …

Pharma majors gear up to launch molnupiravir
2 years, 11 months ago

Pharma majors gear up to launch molnupiravir

The Hindu  

Cipla, Sun Pharma and Dr. Reddy’s Laboratories were among the clutch of pharma firms that on Tuesday said they will soon be launching molnupiravir capsules. Dr. Reddy’s said it would soon launch its molnupiravir 200mg capsules under the brand name Molflu in the country. Prasad said, “The approval to launch molnupiravir is an important development not only as a treatment …

A shot in the arm: The Hindu Editorial on new modes of COVID-19 treatment
3 years ago

A shot in the arm: The Hindu Editorial on new modes of COVID-19 treatment

The Hindu  

If full vaccination using any COVID-19 vaccine greatly reduces a person’s risk of progressing to severe disease and death, then the move by the U.S. FDA to grant emergency-use authorisation to two oral antiviral drugs for certain categories of people who are likely to become severely ill provides a much-needed fillip to fight the disease. Unlike in the case of …

Live updates: Japan approves use of Merck's COVID-19 pill
3 years ago

Live updates: Japan approves use of Merck's COVID-19 pill

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy TOKYO — Japan has approved …

U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19
3 years ago

U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19

LA Times  

U.S. regulators have authorized a second pill against COVID-19: molnupiravir, an antiviral drug from Merck that may help blunt the wave of coronavirus infections. The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions such as obesity and heart disease. Additionally, …

Merck’s at-home antiviral COVID-19 pill approved by US regulator
3 years ago

Merck’s at-home antiviral COVID-19 pill approved by US regulator

Al Jazeera  

United States health regulators have authorised a second antiviral pill against COVID-19, providing another easy-to-use medication to battle the rising tide of Omicron infections. Additionally, Pfizer’s drug was roughly three times more effective in testing than Merck’s, reducing hospitalisation and death by nearly 90 percent among high-risk patients. Merck’s drug is not authorised for use in patients younger than 18 …

Merck's Covid-19 pill Molnupiravir found to reduce hospitalisation, death risks
3 years ago

Merck's Covid-19 pill Molnupiravir found to reduce hospitalisation, death risks

India Today  

As Covid-19 cases peak across the world including the US and the UK, Molnupiravir, an oral drug developed by Merck, could act as a counter. In the phase-III clinical trials, the drug was found to reduce the risk of hospitalisation and death in at-risk, unvaccinated adults, Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory …

Pfizer and Merck covid-19 pills are coming soon in the US, but other countries will have to wait
3 years ago

Pfizer and Merck covid-19 pills are coming soon in the US, but other countries will have to wait

Live Mint  

Promising Covid-19 treatment pills are likely to take longer to reach patients in low- and middle-income countries than in rich ones because of manufacturing and pricing obstacles, despite efforts by drugmakers to make them more available, drug-access advocates and public-health experts say. Yet drug-access advocates and public-health experts express concern that the pills will arrive months later in poor countries …

UK planning to rollout Merck's anti-Covid pill as soon as Christmas: Report
3 years ago

UK planning to rollout Merck's anti-Covid pill as soon as Christmas: Report

Hindustan Times  

The government in the United Kingdom is planning to roll out the antiviral pill against Coronavirus disease as part of an offered treatment against the viral disease, according to a report by Sunday Telegraph. The pill -- Molnupiravir -- has been developed by American pharmaceutical company Merck and has been touted as "game-changing" as it can be taken from the …

Merck’s covid-19 pill backed by FDA advisers
3 years ago

Merck’s covid-19 pill backed by FDA advisers

Live Mint  

An outside panel of scientific advisers to the Food and Drug Administration narrowly recommended the agency authorize the experimental Covid-19 oral antiviral from Merck & Co. and partner Ridgeback Biotherapeutics LP. Several panel members who voted in favor of authorization said use of molnupiravir should be limited to unvaccinated people at high risk of Covid-19 complications, and that while more …

Merck’s covid-19 pill to be reviewed by FDA advisers
3 years ago

Merck’s covid-19 pill to be reviewed by FDA advisers

Live Mint  

An outside panel of scientific advisers to the Food and Drug Administration is scheduled to meet Tuesday to discuss the experimental Covid-19 oral antiviral from Merck & Co. and partner Ridgeback Biotherapeutics LP. Researchers plan to study molnupiravir and Omicron soon but think the drug could be effective because it has been found to work against other Covid-19 variants, the …

Merck asks EU drug regulator to authorise its Covid-19 pill
3 years, 1 month ago

Merck asks EU drug regulator to authorise its Covid-19 pill

Hindustan Times  

The European Medicines Agency said it has received a request from Merck to authorise its coronavirus antiviral, the first pill shown to treat Covid-19. In a statement Tuesday, the EU drug regulator said it had started evaluating molnupiravir, made by Merck and Ridgeback Biotherapeutics, and that a decision could be made within weeks on whether it might be cleared. Last …

Pfizer signs deal with UN-backed group to let other companies make its COVID-19 pill
3 years, 1 month ago

Pfizer signs deal with UN-backed group to let other companies make its COVID-19 pill

Daily Mail  

Pfizer Inc has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill. Pictured: People walk by the Pfizer world headquarters in New York, November 9 Generic drug companies will be allowed to produce the pill for use in 95 countries, making up about 53% of the world's population 'It's quite significant that …

Finally, pills to treat Covid-19! All you need to know about Pfizer's Paxlovid and Merck's Molnupiravir
3 years, 1 month ago

Finally, pills to treat Covid-19! All you need to know about Pfizer's Paxlovid and Merck's Molnupiravir

India Today  

Vaccines have been the primary antidote in the battle against Covid-19 to date, but we could have at least two game-changers in the form of American pharmaceutical giant Pfizer's antiviral pill Paxlovid, and Molnupiravir, manufactured by Merck, Sharp and Dohme, and Ridgeback Biotherapeutics. The preliminary data of Pfizer's experimental antiviral pill to treat Covid-19 shows an 89 per cent decrease …

US govt to buy another $1 bn worth of Merck’s Covid-19 pill
3 years, 1 month ago

US govt to buy another $1 bn worth of Merck’s Covid-19 pill

Live Mint  

The US government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday. The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more. Merck said the government has the right …

UK approves Merck's antiviral COVID pill molnupiravir in world first
3 years, 1 month ago

UK approves Merck's antiviral COVID pill molnupiravir in world first

ABC  

Britain has become the first country in the world to approve Merck's potentially game-changing COVID-19 antiviral pill. Key points: US advisers will meet this month to vote on whether molnupiravir should be authorised Australia has already ordered 300,000 courses Merck is expecting to produce 10 million courses by the end of this year The UK's Medicines and Healthcare products Regulatory …

UK becomes first country to approve Merck's anti-Covid pill molnupiravir
3 years, 1 month ago

UK becomes first country to approve Merck's anti-Covid pill molnupiravir

Hindustan Times  

Britain on Thursday approved the use of Merck's antiviral pill to treat patients suffering from mild to moderate Covid-19, the Medicines and Healthcare products Regulatory Agency announced. Based on the clinical trial data, the drug is most effective when taken during the early stages of infection and the MHRA recommends that it be used within five days of the onset …

Molnupiravir: UK authorizes Merck/Ridgeback Biotherapeutics’ antiviral to treat mild-to-moderate Covid-19
3 years, 1 month ago

Molnupiravir: UK authorizes Merck/Ridgeback Biotherapeutics’ antiviral to treat mild-to-moderate Covid-19

CNN  

CNN — The UK Medicines and Healthcare Products Regulatory Agency said Thursday it had authorized Merck and Ridgeback Biotherapeutics’ oral antiviral, molnupiravir, to treat mild-to-moderate Covid-19 in adults at risk for severe illness. The companies have sought US Food and Drug Administration emergency use authorization for the drug, and the FDA said it will convene its Antimicrobial Drugs Advisory Committee …

UK approves Merck’s antiviral COVID-19 pill in world first move
3 years, 1 month ago

UK approves Merck’s antiviral COVID-19 pill in world first move

Al Jazeera  

Merck’s molnupiravir to be given to recently-infected COVID-19 patients twice a day, for five days. The United Kingdom has become the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics. Merck’s molnupiravir has been closely watched since data last month showed it could halve the chances of dying or …

Merck strikes deal for global access to COVID-19 medication
3 years, 1 month ago

Merck strikes deal for global access to COVID-19 medication

Al Jazeera  

The deal could pave the way for the use of antiviral drug molnupiravir in 105 low- and middle-income countries. The global Medicines Patent Pool, which is backed by the United Nations, said on Wednesday it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access for its antiviral medicine molnupiravir. “The interim results for molnupiravir are compelling …

Cheap antidepressant shows promise treating early COVID-19
3 years, 1 month ago

Cheap antidepressant shows promise treating early COVID-19

LA Times  

SARS-CoV-2 virus particles on the surface of cells cultured in a lab. A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19, according to results of a study hunting for existing drugs that could be repurposed to treat the pandemic disease. The researchers shared their results with the U.S. National Institutes of Health, which publishes COVID-19 treatment …

WHO-led program aims to buy antiviral Covid-19 pills for $10
3 years, 2 months ago

WHO-led program aims to buy antiviral Covid-19 pills for $10

CNN  

A World Health Organization-led program to ensure poorer countries get fair access to Covid-19 vaccines, tests and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as $10 per course, a draft document seen by Reuters says. The document, which outlines the goals of the Access to Covid-19 Tools Accelerator until September next year, says …

Merck Covid pill: Asian countries are rushing to buy molnupiravir but poor countries could miss out
3 years, 2 months ago

Merck Covid pill: Asian countries are rushing to buy molnupiravir but poor countries could miss out

CNN  

CNN — During the global scramble to secure vaccines, many countries in Asia-Pacific were slow off the mark. “This is a game changer.” What the Covid pill means for vaccines Vaccines are still the best protection, say experts – after all, they can reduce the risk of a person getting Covid-19 at all. “This drug will be a frontline solution …

Merck seeks first US authorization for Covid-19 tablet
3 years, 2 months ago

Merck seeks first US authorization for Covid-19 tablet

Live Mint  

Merck & Co Inc said on Monday it has applied for US emergency use authorization for its tablet to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease. An authorization from the US Food and Drug Administration could help change clinical management of COVID-19 as the pill can be taken …

Merck seeks FDA emergency use authorization for experimental antiviral Covid-19 treatment molnupiravir
3 years, 2 months ago

Merck seeks FDA emergency use authorization for experimental antiviral Covid-19 treatment molnupiravir

CNN  

CNN — Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir. “At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of placebo-treated patients,” …

Merck seeks US authorisation for pill to treat COVID
3 years, 2 months ago

Merck seeks US authorisation for pill to treat COVID

Al Jazeera  

US pharmaceutical giant submits request for FDA approval for molnupiravir pill to treat mild-to-moderate COVID-19 cases. US pharmaceutical company Merck has requested emergency authorisation for its experimental pill to treat mild-to-moderate cases of COVID-19, in what would add a promising, new tool to the global fight against the virus. Merck submitted the application for molnupiravir, which it said earlier this …

Covid pill makers accused of selling drug to US at 40 times what it costs
3 years, 2 months ago

Covid pill makers accused of selling drug to US at 40 times what it costs

The Independent  

The latest headlines from our reporters across the US sent straight to your inbox each weekday Your briefing on the latest headlines from across the US Your briefing on the latest headlines from across the US SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy The company producing an …

EXPLAINED: A Pill You Can Pop At Home To Beat Covid. Here's Why Merck's Antiviral Drug Is Raising Hopes
3 years, 2 months ago

EXPLAINED: A Pill You Can Pop At Home To Beat Covid. Here's Why Merck's Antiviral Drug Is Raising Hopes

News 18  

The global death toll from Covid-19 is said to now have crossed 5 million even as the pandemic’s end is yet to appear within sight. Merck, which has partnered the US-based Ridgeback Biotherapeutics for the development of the drug, said that Phase-3 trials showed that it “significantly reduced the risk of hospitalisation or death… in at risk, non-hospitalised adult patients …

Explained | Molnupiravir, Merck’s new drug to treat COVID-19
3 years, 2 months ago

Explained | Molnupiravir, Merck’s new drug to treat COVID-19

The Hindu  

Why is there much excitement about molnupiravir, the investigational new drug for COVID-19? Pharmaceutical major Merck and Ridgeback Biotherapeutics announced via a press release on October 1 the early results from Phase-3 trials that its anti-viral drug molnupiravir halved the chances of hospitalisation in COVID-19 patients with mild or moderate disease. Several noted clinicians have said that these are promising …

Discover Related